trending Market Intelligence /marketintelligence/en/news-insights/trending/hjlc4omhf7fptrvaozaryg2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Takeda partners with Ambys Medicines to develop liver disease treatments

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates


Takeda partners with Ambys Medicines to develop liver disease treatments

Japan's Takeda Pharmaceutical Co. Ltd. said it will collaborate with biotechnology startup Ambys Medicines to discover and develop therapies for serious liver diseases.

Takeda will invest $100 million in the partnership, that includes its participation in Ambys Medicines' series A financing round to raise $60 million.

The Japanese drugmaker will have the option to license the first four products that reach regulatory submission globally, except the U.S. where Ambys retains full rights.

If Takeda exercises its licensing option, it will share half of the development costs for any chosen product and will make regulatory and milestone payments to the startup company.

Based in Redwood City, Calif., and backed by private equity firm Third Rock Ventures, Ambys Medicines is focused on developing therapies capable of restoring liver function, preventing the progression of liver disease, and treating the devastating complications of liver failure.